To investigate the efficacy of Avelumab when given in combination with paclitaxel as a first
line treatment for the patients with inoperable angiosarcoma.
Angiosarcomas are very rare tumors (incidence < 1/100.000/year) of vascular or lymphatic
origin characterized by a clinical heterogeneity in terms of presentation and behavior.In
several prospective and retrospective studies, weekly paclitaxel showed promising activity in
patients with advanced or metastatic angiosarcoma. Given the important role of PD-L1 in the
suppression of T-cell responses, and the mode of action of avelumab which blocks the
interaction between PD-L1 and its receptors, avelumab is being developed as a potential
therapy for subjects with various tumors. In prior study cutaneous angiosarcoma patients with
a high infiltration of PD-1-positive cells with tumor site PD-L1 expression were more likely
to have favorable survival.
Therefore, antitumor activity of Avelumab as inhibitor of PD-1/PDL-1 interaction with
Paclitaxel, standard chemotherapy, might have more therapeutic improvement.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.